{"id":973617,"date":"2026-06-18T08:47:10","date_gmt":"2026-06-18T12:47:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\/"},"modified":"2026-06-18T08:47:10","modified_gmt":"2026-06-18T12:47:10","slug":"berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\/","title":{"rendered":"Berger Montague PC Investigating Claims on Behalf of ADMA Biologics, Inc. (NASDAQ: ADMA) Investors After Class Action Filing"},"content":{"rendered":"
\n

PHILADELPHIA, June 18, 2026 (GLOBE NEWSWIRE) — National plaintiffs\u2019 law firm Berger Montague PC<\/u><\/a> announces a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA)<\/strong> (\u201cADMA\u201d or the \u201cCompany\u201d) on behalf of investors who purchased or acquired ADMA common stock during the period from August 9, 2024 through March 25, 2026<\/strong> (the \u201cClass Period\u201d).<\/p>\n

\n
\n Investor Deadline:<\/em>
\n <\/strong>
\n Investors who purchased or acquired ADMA securities during the Class Period may, no later than <\/em>
\n
\n August 10, 2026<\/em>
\n <\/strong>
\n , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, <\/em>
\n
\n
\n
\n CLICK HERE<\/u>
\n <\/em>
\n <\/strong>
\n <\/a>
\n .<\/em>\n <\/p>\n

Headquartered in Ramsey, NJ, ADMA is a biopharmaceutical company focused on the development of specialty biologics, including treatments for immune deficiencies and infectious diseases. Its flagship product, ASCENIV, is a liquid immune globulin therapy used to treat Primary Humoral Immunodeficiency.<\/p>\n

According to the lawsuit, during the Class Period, ADMA was engaged in a channel-stuffing scheme intended to drive revenue growth in the face of declining demand for ASCENIV. The suit also alleges that ADMA failed to disclose related party transactions.<\/p>\n

On March 24, 2026, financial analyst Culper Research published a report titled, \u201cADMA Biologics Inc (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and \u20133% Real Growth in 2025 vs. +20% Reported.\u201d The report asserted that in 2025, ADMA was able to \u201creport revenue growth that was never there\u201d by inducing one of its distributors to \u201cstock excess ASCENIV by offering rebates and extended payment terms\u2026.\u201d According to Culper Research, had ADMA not engaged in this alleged channel stuffing scheme, it would have experienced revenue declines of 3% in 2025 instead of the reported 20% growth.<\/p>\n

On this news, ADMA shares declined $2.26 per share, or 16%, from a closing price of $13.59 per share on March 23, 2026, to a close of $11.33 per share on March 24, 2026. Shares fell an additional $1.70 per share (15%) the following day, closing at $9.63 per share on March 25, 2026.<\/p>\n

\n
\n If you are an ADMA investor and would like to learn more about this action, <\/em>
\n <\/strong>
\n
\n
\n
\n CLICK HERE<\/u>
\n <\/em>
\n <\/strong>
\n <\/a>
\n
\n or please contact Berger Montague: Andrew Abramowitz at <\/em>
\n <\/strong>
\n
\n
\n
\n aabramowitz@bergermontague.com<\/u>
\n <\/em>
\n <\/strong>
\n <\/a>
\n
\n or (215) 875-3015, or Caitlin Adorni at <\/em>
\n <\/strong>
\n
\n
\n
\n cadorni@bergermontague.com<\/u>
\n <\/em>
\n <\/strong>
\n <\/a>
\n
\n or (267) 764-4865.<\/em>
\n <\/strong>\n <\/p>\n

\n About Berger Montague<\/strong>\n <\/p>\n

Berger Montague is one of the nation\u2019s preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.<\/p>\n

For more information or to discuss your rights, please contact:<\/p>\n

\n Andrew Abramowitz<\/strong>
\n
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com<\/p>\n

\n Caitlin Adorni<\/strong>
\n
Berger Montague
(267) 764-4865
cadorni@bergermontague.com<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

PHILADELPHIA, June 18, 2026 (GLOBE NEWSWIRE) — National plaintiffs\u2019 law firm Berger Montague PC announces a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) (\u201cADMA\u201d or the \u201cCompany\u201d) on behalf of investors who purchased or acquired ADMA common stock during the period from August 9, 2024 through March 25, 2026 (the \u201cClass Period\u201d). Investor Deadline: Investors who purchased or acquired ADMA securities during the Class Period may, no later than August 10, 2026 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE . Headquartered in Ramsey, NJ, ADMA is a biopharmaceutical company focused on the development of specialty biologics, including treatments for immune deficiencies and infectious diseases. Its flagship … <\/p>\n

Continue reading “Berger Montague PC Investigating Claims on Behalf of ADMA Biologics, Inc. (NASDAQ: ADMA) Investors After Class Action Filing”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-973617","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBerger Montague PC Investigating Claims on Behalf of ADMA Biologics, Inc. (NASDAQ: ADMA) Investors After Class Action Filing - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Berger Montague PC Investigating Claims on Behalf of ADMA Biologics, Inc. (NASDAQ: ADMA) Investors After Class Action Filing - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA, June 18, 2026 (GLOBE NEWSWIRE) — National plaintiffs\u2019 law firm Berger Montague PC announces a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) (\u201cADMA\u201d or the \u201cCompany\u201d) on behalf of investors who purchased or acquired ADMA common stock during the period from August 9, 2024 through March 25, 2026 (the \u201cClass Period\u201d). Investor Deadline: Investors who purchased or acquired ADMA securities during the Class Period may, no later than August 10, 2026 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE . Headquartered in Ramsey, NJ, ADMA is a biopharmaceutical company focused on the development of specialty biologics, including treatments for immune deficiencies and infectious diseases. Its flagship … Continue reading "Berger Montague PC Investigating Claims on Behalf of ADMA Biologics, Inc. (NASDAQ: ADMA) Investors After Class Action Filing"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-18T12:47:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0OTAwMiM3NjYzMzI3IzIwODI5NjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Berger Montague PC Investigating Claims on Behalf of ADMA Biologics, Inc. (NASDAQ: ADMA) Investors After Class Action Filing\",\"datePublished\":\"2026-06-18T12:47:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\\\/\"},\"wordCount\":497,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0OTAwMiM3NjYzMzI3IzIwODI5NjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\\\/\",\"name\":\"Berger Montague PC Investigating Claims on Behalf of ADMA Biologics, Inc. (NASDAQ: ADMA) Investors After Class Action Filing - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0OTAwMiM3NjYzMzI3IzIwODI5NjI=\",\"datePublished\":\"2026-06-18T12:47:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0OTAwMiM3NjYzMzI3IzIwODI5NjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0OTAwMiM3NjYzMzI3IzIwODI5NjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Berger Montague PC Investigating Claims on Behalf of ADMA Biologics, Inc. (NASDAQ: ADMA) Investors After Class Action Filing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Berger Montague PC Investigating Claims on Behalf of ADMA Biologics, Inc. (NASDAQ: ADMA) Investors After Class Action Filing - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\/","og_locale":"en_US","og_type":"article","og_title":"Berger Montague PC Investigating Claims on Behalf of ADMA Biologics, Inc. (NASDAQ: ADMA) Investors After Class Action Filing - Market Newsdesk","og_description":"PHILADELPHIA, June 18, 2026 (GLOBE NEWSWIRE) — National plaintiffs\u2019 law firm Berger Montague PC announces a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) (\u201cADMA\u201d or the \u201cCompany\u201d) on behalf of investors who purchased or acquired ADMA common stock during the period from August 9, 2024 through March 25, 2026 (the \u201cClass Period\u201d). Investor Deadline: Investors who purchased or acquired ADMA securities during the Class Period may, no later than August 10, 2026 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE . Headquartered in Ramsey, NJ, ADMA is a biopharmaceutical company focused on the development of specialty biologics, including treatments for immune deficiencies and infectious diseases. Its flagship … Continue reading \"Berger Montague PC Investigating Claims on Behalf of ADMA Biologics, Inc. (NASDAQ: ADMA) Investors After Class Action Filing\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-18T12:47:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0OTAwMiM3NjYzMzI3IzIwODI5NjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Berger Montague PC Investigating Claims on Behalf of ADMA Biologics, Inc. (NASDAQ: ADMA) Investors After Class Action Filing","datePublished":"2026-06-18T12:47:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\/"},"wordCount":497,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0OTAwMiM3NjYzMzI3IzIwODI5NjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\/","name":"Berger Montague PC Investigating Claims on Behalf of ADMA Biologics, Inc. (NASDAQ: ADMA) Investors After Class Action Filing - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0OTAwMiM3NjYzMzI3IzIwODI5NjI=","datePublished":"2026-06-18T12:47:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0OTAwMiM3NjYzMzI3IzIwODI5NjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0OTAwMiM3NjYzMzI3IzIwODI5NjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/berger-montague-pc-investigating-claims-on-behalf-of-adma-biologics-inc-nasdaq-adma-investors-after-class-action-filing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Berger Montague PC Investigating Claims on Behalf of ADMA Biologics, Inc. (NASDAQ: ADMA) Investors After Class Action Filing"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/973617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=973617"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/973617\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=973617"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=973617"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=973617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}